Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with ...

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

Elevations in biomarkers such as uterine artery pulsatility index and placental growth factor throughout pregnancy indicate ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...